Photo of Mamatha Mandava, M.D.

Mamatha Mandava, M.D.

  • Center for Cancer Research
  • National Cancer Institute
Immune Deficiency Cellular Therapy Program


Dr. Mandava's main research interests include hematopoietic stem cell transplantation (HSCT) for non-malignant diseases with a focus on primary immune deficiency disorders and immune regulatory disorders, improving post-transplant outcomes, and viral infections post-transplant and long-term follow-up.

Areas of Expertise

Pediatric Hematopoietic Cell Transplantation
Primary Immune Deficiency And Immune Regulatory Disorders

Information for Patients

Learn more about our clinical trials and the highly specialized care team that lead them.


Selected Recent Publications

Outcomes following posttransplant viral-specific T-cell therapy in patients with sickle cell disease

Kinoshita H, Mandava M, Jensen-Wachspress MA, Lang H, Joy E, Tanna J, McCann CD, O'Brien S, Burnett S, Shibli A, Hoq F, Bhatia M, Hanley PJ, Dávila Saldaña BJ, Mahadeo KM, Bollard CM, Keller MD, Abraham AA
Blood Advances. Volume 7 Issue 10: 2105-2116, 2023. [ Journal Article ]

Mass cytometric analysis of the immune cell landscape after traumatic brain injury elucidates the role of complement and complement receptors in neurologic outcomes

Toutonji A, Krieg C, Borucki DM, Mandava M, Guglietta S, Tomlinson S.
Acta Neuropathologica Communications. Volume 11 Issue 1: 92, 2023. [ Journal Article ]

Chronic complement dysregulation drives neuroinflammation after traumatic brain injury: a transcriptomic study

Toutonji A, Mandava M, Guglietta S, Tomlinson S
Acta Neuropathologica Communications. Volume 9 Issue 1: 126, 2021. [ Journal Article ]